Organisation paid for research Program year 2025 Source: CMS Open Payments

Panax Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,296,875

194 payments

Through program year 2025, Panax Clinical Research LLC is reported as receiving $2,296,875 in research payments, across 194 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$553,376	28
2024	Research	$88,216	6
2023	Research	$375,236	22
2022	Research	$372,343	39
2021	Research	$366,567	23
2020	Research	$246,542	42
2019	Research	$294,596	34

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $640,083 24 payments
Pfizer Inc. $432,277 42 payments
Genentech, Inc. $354,872 18 payments
Allergan Inc. $242,360 36 payments
Bavarian Nordic A/S $185,340 4 payments
AbbVie, Inc. $141,591 41 payments
ITI, Inc. $94,415 4 payments
Ardelyx, Inc. $72,070 6 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $56,244 3 payments
Eisai Inc. $54,795 12 payments

Studies the money was for Research payments · program years 2019–2025

Cpet $354,872 18 payments
A Phase 1 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability and Immunogenicity of Selfamplifying Rna Vaccine Preparations Against Influenza in Healthy Individuals $299,805 29 payments
A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $287,787 3 payments
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $182,620 15 payments
M16-100 $107,483 23 payments
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years $102,671 2 payments
A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetics of ITI-1284 in Subjects with Normal and Impaired Hepatic Function $94,415 4 payments
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years $82,669 2 payments
A Phase 3 Parallel-Design Open-Label Randomized Controlled Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared to Insulin Glargine in Adults With Type 2 Diabetes on Multiple Daily Injections $82,536 2 payments
Phase 2A Hepatic Impairment $82,184 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.